BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/30/2016 2:15:00 PM | Browse: 946 | Download: 1315
 |
Received |
|
2015-07-28 14:22 |
 |
Peer-Review Started |
|
2015-07-29 15:34 |
 |
To Make the First Decision |
|
2015-10-27 11:24 |
 |
Return for Revision |
|
2015-11-03 09:00 |
 |
Revised |
|
2015-12-05 03:50 |
 |
Second Decision |
|
2015-12-28 14:07 |
 |
Accepted by Journal Editor-in-Chief |
|
|
 |
Accepted by Executive Editor-in-Chief |
|
2016-01-11 15:44 |
 |
Articles in Press |
|
2016-01-11 15:44 |
 |
Publication Fee Transferred |
|
|
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
2016-03-21 10:23 |
 |
Publish the Manuscript Online |
|
2016-03-30 14:14 |
ISSN |
1948-5204 (online) |
Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
|
Copyright |
© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved. |
Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
Category |
Oncology |
Manuscript Type |
Review |
Article Title |
Chromodomain-helicase-DNA binding protein 5, 7 and pronecrotic mixed lineage kinase domain-like protein serve as potential prognostic biomarkers in patients with resected pancreatic adenocarcinomas
|
Manuscript Source |
Invited Manuscript |
All Author List |
Crystal S Seldon, Lauren E Colbert, William A Hall, Sarah B Fisher, David S Yu and Jerome C Landry |
Funding Agency and Grant Number |
Funding Agency |
Grant Number |
National Center for Advancing Translational Sciences of the National Institutes of Health |
ULl TR000454 (to Dr. Colbert and Dr. Fisher) |
National Center for Advancing Translational Sciences of the National Institutes of Health |
TLlTR000456 (to Dr. Colbert) |
Pancreatic Cancer Action Network (Pan-CAN)&solAmerican Association for Cancer Research (AACR) |
16982 (to Dr. Yu) |
Department of Defense (DOD)/ Peer Reviewed Cancer Research Program (PRCRP) |
CA110535 (to Dr. Yu) |
Georgia Cancer Coalition |
11072 (to Dr. Yu) |
|
Corresponding Author |
Jerome C Landry, MD, MBA, Assistant Professor, Department of Radiation Oncology, Winship Cancer Institute, Emory University School of Medicine, 1365 Clifton Road, NE, Suite C3008, Atlanta, GA 30322, United States. jland01@emory.edu |
Key Words |
Chromodomain-helicase-DNA binding protein 5; Chromodomain-helicase-DNA binding protein 7; Mixed lineage kinase domain-like protein; Pancreatic adenocarcinoma; Biomarker |
Core Tip |
Pancreatic cancer is one of the deadliest cancers with a very poor prognosis. Recently, there has been a significant increase in studies and research directed towards identifying potential biomarkers that can be used to diagnose and provide prognostic information for pancreatic cancer. We focused on 3 biomarkers involved in the DNA damage response pathway and the necroptosis pathway: Chromodomain-helicase-DNA binding protein 5, chromodomain-helicase-DNA binding protein 7, and mixed lineage kinase domain-like protein. Based on the data presented, these biomarkers warrant further investigation. |
Publish Date |
2016-03-30 14:14 |
Citation |
Seldon CS, Colbert LE, Hall WA, Fisher SB, Yu DS, Landry JC. Chromodomain-helicase-DNA binding protein 5, 7 and pronecrotic mixed lineage kinase domain-like protein serve as potential prognostic biomarkers in patients with resected pancreatic adenocarcinomas. World J Gastrointest Oncol 2016; 8(4): 358-365 |
URL |
http://www.wjgnet.com/1948-5204/full/v8/i4/358.htm |
DOI |
http://dx.doi.org/10.4251/wjgo.v8.i4.358 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345